Suchergebnisse

Frontmatter -- Inhalt -- Abkürzungsverzeichnis -- Vorwort -- 1. Einleitung -- 2. Rahmenbedingungen der Krankenhauspolitik -- 3. Rückblick auf die Krankenhausfinanzierung und -planung in Bayern und Nordrhein-Westfalen vor 1972 -- 4. Implementation des KHG in Bayern und Nordrhein-Westfalen -- 5. Umsetzungsmechanismen der Krankenhausbedarfsplanung und -finanzierung im politisch-administrativen System Bayerns -- 6. Umsetzungsmechanismen im politisch-administrativen System Nordrhein-Westfalens -- 7. Ergebnisse Implementierter Krankenhauspolitik über einen Zeitraum von 30 Jahren -- 8. Schlußbetrachtungen: Grenzen der Krankenhauspolitik -- Anmerkungen -- Literatur

"Japan is suffering from a "device gap." Compared to its American and European counterparts, Japan lags in adopting innovative medical devices and making new treatments and procedures available to its patients. Many blame its government and bureaucracy for Japan's delayed access to modern medicine and new medical devices. Christa Altenstetter examines the contextual social, historical, and political conditions of Japan's medical field to make sense of the state of the country's medical profession and its regulatory framework. She explores the development of regulatory frameworks and considers possibilities for eventual reform and modernization. More specifically, Altenstetter looks into how physicians and device companies connect to the government and bureaucracy, the relationships connecting Japanese patients to their medical system and governmental bureaucracy, and how the relationships between policymakers and the medical profession are changing. The issues addressed here are becoming increasingly relevant as numerous countries in Asia, Latin America, and Central and Eastern Europe are only now beginning to regulate medical technology, following the lead of the US and the European Union. Those interested in global medicine and Asian studies will find this book both informative and compelling."--Provided by publisher.

The literature on the regulation of drugs at the FDA and the European Union is substantial, yet little research has provided comparative analyses and robust empirical data on the regulation of medical devices in the United States and the European Union. As medical and health markets become increasingly globalized, and the U.S. and the EU compete for leadership and recognition, salient domestic regulatory issues are becoming increasingly international and transnational policy issues. Building on Carpenter's (2010) work on drug regulation at the FDA, but taking a slightly narrower yet at the same time a broader approach by drawing on interdisciplinary studies instead of limiting ourselves to only the Political Science literature, this comparison focuses on key aspects of risk regulation and governance of medical devices in the U.S. and the EU, and shows how and why individual and organizational learning is imperative in each case.

German Statutory Health Insurance (national health insurance) has remained relatively intact over the past century, even in the face of governmental change and recent reforms.